Digoxin
Product Images NDC 21695-678

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Digoxin (NDC 21695-678). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rebel Distributors Corp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Of Formula (Cabd1834 7398 497e B11f 221a25f21a4e 01)

FDA Label Image

Table 1 (Cabd1834 7398 497e B11f 221a25f21a4e 02)

Table 1 provides a comparison of the systemic availability and equivalent doses for different oral preparations of Digoxin, which is used to treat heart failure and abnormal heart rhythms. The table lists different dosage forms, such as tablets, elixir pediatric, solution in capsules, and injection/lV, along with their bioavailability percentages and absolute equivalent doses in mcg. For instance, it shows that 125 mcg Digoxin Tablets is equal to 125 mcg Digoxin Elixir Pediatric, which is equivalent to 100 mcg Digoxin Solution in Capsules, and so on.*

FDA Label Image

Table 2 (Cabd1834 7398 497e B11f 221a25f21a4e 03)

This is a table showing the times it takes for various preparations of Digoxin to have a pharmacological effect and to reach peak effect. The preparations include Tablets, Elixir Pediatric, Solution in Capsules, and InjectionV. The onset of effect ranges from 0.5 to 2 hours for all preparations, while the peak effect ranges from 2 to 6 hours. The effects documented for ventricular response rate in atrial fibrillation, inotropic effects, and electrocardiographic changes vary depending on the rate of infusion.*

FDA Label Image

Table 3 (Cabd1834 7398 497e B11f 221a25f21a4e 04)

The given text appears to be a table showing Subgroup Analyses of Mortality and Hospitalization occurring during the first 2 years post-randomization in participants with different conditions. The table comprises various columns related to different groups and their risks of occurrence of hospitalization or mortality. The relative risk with 95% confidence intervals is also mentioned for each patient subgroup. The title of the table mentions "Dig Ancillary Study."*

FDA Label Image

Table 4 (Cabd1834 7398 497e B11f 221a25f21a4e 05)

Table 4 shows the adverse experiences reported by patients in two double-blind withdrawal trials of Digoxin and Placebo. The adverse experiences are categorized as Cardiac, Gastrointestinal, Headache, Mental Disturbances, and Other. The number of patients reporting each adverse experience for Digoxin and Placebo are listed separately.*

FDA Label Image

Table 4 (Cabd1834 7398 497e B11f 221a25f21a4e 06)

Table 4 provides information on adverse experiences in two parallel, double-blind, placebo-controlled withdrawal trials. The table lists the number of patients reporting adverse experiences for digoxin patients and placebo patients. Adverse experiences include cardiac issues such as palpitation, ventricular extrasystole, tachycardia, and heart arrest, gastrointestinal issues such as anorexia, nausea, vomiting, diarrhea, and abdominal pain. Other adverse experiences include headache, mental disturbances, rash, and even death.*

FDA Label Image

Table 5 (Cabd1834 7398 497e B11f 221a25f21a4e 07)

This appears to be a table showing the usual daily maintenance dose requirements of Digoxin for estimated peak body stores of 10 mcg/kg based on different factors such as corrected creatinine clearance, lean body weight, and number of days before steady state is achieved. The table provides different dosage requirements in mcg for different body weights and factors such as age and gender. The note also provides a formula for estimating creatinine clearance in men and women based on their serum creatinine concentration.*

FDA Label Image

Table 6 (Cabd1834 7398 497e B11f 221a25f21a4e 08)

This is a table displaying daily maintenance doses for children with normal renal function, based on age and weight. There are three age groups listed, with corresponding recommended daily dosages in micrograms per kilogram (mcg/kg) of body weight.*

FDA Label Image

Digoxin 125mcg (0.125mg) (Cabd1834 7398 497e B11f 221a25f21a4e 09)

This is a description of a medication called Digoxin in the form of 30 tablets with a strength of 125mcg (0.125mg). The National Drug Code (NDC) is 21695-678-30, and the medication is manufactured by Jerome Stevens Pharmaceuticals in Bohemia, New York. The tablets come with a prescription and have a lot number of 00000 with an expiration date of 00/00/00. The medication should be kept out of the reach of children and stored at a temperature of 59°-86°F. The average wholesale price (AWP) of the medication is $26.65.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.